BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $75

BTIG analyst Kambiz Yazdi has maintained a Buy rating on Rapport Therapeutics (NASDAQ: RAPP) and raised the price target from $65 to $75. This adjustment reflects a positive outlook on the company's performance.